Can regenerative medicine save Big Pharma’s business model from the patent cliff?

Regen Med. 2010 Sep;5(5):687-90. doi: 10.2217/rme.10.68.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Commerce*
  • Patents as Topic*
  • Regenerative Medicine / legislation & jurisprudence
  • Regenerative Medicine / methods*